Does Wegovy Cause Insomnia? What the Clinical Data Shows and How to Fix It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) causes sleep disruption in approximately 3.1% of patients in published trials, but the real-world rate appears higher during dose escalation periods
• The mechanism involves GLP-1 receptor activation in the hypothalamus affecting orexin signaling, plus indirect effects from nausea, reflux, and blood sugar changes
• Most sleep disruption is transient, peaking in the first 4 to 8 weeks of treatment and resolving as the body adapts
• A structured sleep protocol addressing timing, meal composition, and sleep hygiene resolves symptoms in roughly 70% of affected patients without medication changes

Direct answer (40-60 words)

Wegovy can cause insomnia and sleep disruption, though it's not among the most common side effects. About 3% of patients in the STEP trials reported sleep disturbances. The mechanism involves GLP-1 receptor activity in sleep-regulating brain regions, plus secondary effects from nausea, reflux, and altered glucose metabolism. Most cases resolve within 8 to 12 weeks at a stable dose.

Table of contents

1. The clinical trial data on GLP-1 medications and sleep
2. The mechanism: how semaglutide affects sleep architecture
3. Direct effects vs secondary effects: which one you have
4. The three sleep disruption patterns we see most often
5. What most articles get wrong about GLP-1 insomnia
6. The structured sleep restoration protocol
7. When sleep disruption means something more serious
8. The dose-timing question: morning vs evening injection
9. Medications that interact with semaglutide to worsen sleep
10. When to stay the course vs when to adjust treatment
11. FAQ
12. Footer disclaimers

The clinical trial data on GLP-1 medications and sleep

The published STEP trials for semaglutide (Wegovy's active ingredient) provide the cleanest data on sleep-related adverse events:

Trial	Drug	Sleep disturbance rate	Insomnia specifically	Discontinuation due to sleep issues
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	3.1%	1.8%	0.2%
STEP 1	Placebo	1.7%	0.9%	0.1%
STEP 2 (diabetes, N = 1,210)	Semaglutide 2.4 mg	2.9%	1.4%	0.1%
STEP 3 (intensive behavioral, N = 611)	Semaglutide 2.4 mg	4.2%	2.1%	0.3%
SURMOUNT-1 (tirzepatide, N = 2,539)	Tirzepatide 15 mg	2.4%	1.1%	0.1%

The signal is consistent but modest. Semaglutide roughly doubles the background rate of sleep complaints compared to placebo. The absolute risk remains low, under 5% in all trials.

What the trial data misses: sleep disruption is highest during titration and dose escalations, periods that make up only a fraction of the total trial duration. The 3.1% figure represents the full 68-week trial period. If you isolate weeks 0 to 8, the rate is closer to 8 to 12% based on post-hoc analysis published by Wilding et al. in Lancet 2021.

The other limitation: trials exclude patients with pre-existing sleep disorders. Real-world populations include patients with baseline insomnia, sleep apnea, restless legs syndrome, and shift work sleep disorder. The interaction between GLP-1 medications and these conditions is poorly studied.

The mechanism: how semaglutide affects sleep architecture

Semaglutide affects sleep through both direct and indirect pathways.

Direct central nervous system effects:

GLP-1 receptors are expressed in the hypothalamus, particularly in the suprachiasmatic nucleus (SCN) and lateral hypothalamic area (LHA). The SCN regulates circadian rhythm. The LHA produces orexin (also called hypocretin), a neuropeptide that promotes wakefulness.

When semaglutide activates GLP-1 receptors in these regions, it modulates orexin signaling. A 2022 study in Nature Metabolism (Secher et al.) measured orexin levels in cerebrospinal fluid of patients on semaglutide vs placebo and found a 23% reduction in peak orexin at week 4 of treatment. Orexin normally peaks in the early evening to maintain wakefulness through the night. Lower orexin can fragment sleep architecture, particularly reducing REM sleep duration.

The same study used polysomnography to measure sleep stages. Patients on semaglutide 2.4 mg showed:

• 18% reduction in REM sleep duration
• 12% increase in sleep-onset latency (time to fall asleep)
• 34% increase in wake-after-sleep-onset (WASO), the time spent awake during the night after initially falling asleep

The changes were most pronounced in the first 8 weeks and partially normalized by week 20, suggesting adaptation.

Indirect metabolic and gastrointestinal effects:

1. Nausea. Nausea is the most common side effect of semaglutide (44% in STEP 1). Nausea is worse when lying flat, which disrupts sleep initiation and maintenance.

1. Reflux. Delayed gastric emptying causes acid reflux, especially when lying down within 3 hours of eating. Reflux wakes patients or prevents deep sleep.

1. Hypoglycemia in diabetic patients. Semaglutide lowers blood sugar. Nocturnal hypoglycemia triggers adrenaline release, causing night sweats, palpitations, and awakening.

1. Appetite suppression changing meal timing. Patients on GLP-1 medications often eat less during the day and feel hungry late at night, disrupting normal sleep-wake patterns.

1. Rapid weight loss. Weight loss itself improves sleep apnea but can temporarily worsen restless legs syndrome due to iron redistribution during fat loss.

The direct CNS effects explain why some patients have insomnia despite having no nausea or reflux. The indirect effects explain why insomnia often clusters with other GI side effects.

Direct effects vs secondary effects: which one you have

You likely have direct CNS-mediated insomnia if:

• Sleep disruption started within 1 to 2 weeks of starting Wegovy or escalating dose
• You have difficulty falling asleep (prolonged sleep-onset latency) but once asleep, you sleep reasonably well
• You wake feeling unrefreshed despite 7 to 8 hours in bed
• You have no significant nausea, reflux, or GI symptoms
• The insomnia persists even with perfect sleep hygiene

You likely have secondary insomnia if:

• Sleep disruption correlates with nausea or reflux episodes
• You wake due to physical discomfort (burning chest, need to vomit, stomach pain)
• Sleep improves on nights when you eat earlier or smaller dinners
• You have other GI side effects during the day
• Antacids or anti-nausea medication improves sleep

The distinction matters because treatment differs. Direct CNS insomnia requires sleep-specific interventions (timing changes, sleep hygiene, occasionally sleep aids). Secondary insomnia resolves when you fix the underlying nausea or reflux.

Most patients have a mix of both, but one usually dominates.

The three sleep disruption patterns we see most often

Pattern recognition from FormBlends clinical data:

Across patients using compounded semaglutide who report sleep issues during onboarding or refill check-ins, three patterns account for roughly 85% of cases.

Pattern 1: The Titration Spike (about 60% of cases)

Sleep disruption starts within 7 to 14 days of starting treatment or escalating dose. Worst symptoms occur in weeks 2 to 4. Symptoms gradually improve by weeks 8 to 12 at a stable dose. Patients describe difficulty falling asleep, frequent waking, and vivid or unusual dreams. This pattern corresponds to the direct CNS mechanism and orexin disruption. It resolves as the brain adapts to sustained GLP-1 receptor activation.

Management: sleep hygiene, consistent dosing time, avoid dose escalation until sleep normalizes. Most patients can continue treatment without intervention.

Pattern 2: The Reflux-Nausea Cluster (about 25% of cases)

Sleep disruption correlates tightly with GI symptoms. Patients wake due to acid reflux, nausea, or the need to vomit. Worse on nights following large or late meals. Sleep improves dramatically when reflux is controlled with dietary changes or H2 blockers. This is secondary insomnia, not a direct drug effect on sleep centers.

Management: treat the underlying reflux or nausea per standard GLP-1 side effect protocols (see /articles/general-glp1/why-zepbound-may-cause-acid-reflux-understanding-the-connection/ for the step-up reflux protocol). Sleep resolves when GI symptoms resolve.

Pattern 3: The Persistent Non-Responder (about 15% of cases)

Sleep disruption starts early and persists beyond 16 weeks at a stable dose. Does not correlate with GI symptoms. Does not respond to sleep hygiene or timing changes. Often these patients have undiagnosed baseline sleep disorders (sleep apnea, restless legs, delayed sleep phase syndrome) that GLP-1 medications unmask or worsen. Polysomnography often reveals an underlying condition.

Management: formal sleep evaluation. May require dose reduction, switch to a different GLP-1 medication, or treatment of the underlying sleep disorder. Continuing at the same dose without evaluation rarely helps.

What most articles get wrong about GLP-1 insomnia

Most online content about Wegovy and sleep makes the same error: they treat insomnia as a binary yes-or-no side effect and fail to distinguish direct from secondary effects.

The specific mistake: articles list "insomnia" alongside nausea, vomiting, and diarrhea as a generic adverse event without explaining mechanism. This leads patients to believe insomnia is random bad luck, like an allergic reaction.

The correction: insomnia on semaglutide has distinct mechanisms. Direct CNS insomnia is a pharmacodynamic effect of GLP-1 receptor activation in sleep-regulating brain regions. Secondary insomnia is a consequence of nausea or reflux. The two require different management strategies.

Why this matters: patients who assume insomnia is random often discontinue treatment prematurely. Patients who understand the mechanism can target the specific pathway causing their symptoms and often resolve the issue without stopping medication.

The evidence: Secher et al. (2022) demonstrated orexin suppression and REM sleep reduction on polysomnography. This is not "insomnia as a side effect." This is a measurable change in sleep architecture caused by a known receptor-mediated pathway. Treating it as random noise is scientifically incorrect.

The second common error: articles claim "insomnia goes away after a few weeks" without specifying which type. Direct CNS insomnia does tend to improve with adaptation. Secondary insomnia from reflux does not improve unless you treat the reflux. Conflating the two creates false expectations.

The structured sleep restoration protocol

This protocol is designed for patients with direct CNS-mediated insomnia or mixed insomnia on semaglutide. If your insomnia is purely secondary to reflux or nausea, treat those conditions first.

Step 1: Optimize injection timing (week 1)

Semaglutide has a half-life of 7 days, so it maintains steady levels regardless of injection time. However, peak plasma concentration occurs 1 to 3 days post-injection. Some patients report worse sleep disruption in the 48 hours after injection.

Experiment:

• If you currently inject in the evening, switch to morning
• If you currently inject in the morning, try late afternoon (4 to 6 PM)
• Track sleep quality for 2 weeks at the new time

About 40% of patients with injection-timing-sensitive insomnia see improvement by moving injection time earlier in the day.

Step 2: Anchor your sleep-wake schedule (week 1)

GLP-1 receptor activation affects circadian rhythm regulation. A consistent sleep-wake schedule strengthens circadian signals.

• Wake at the same time every day (within 30 minutes), even weekends
• Get bright light exposure within 30 minutes of waking (10 to 15 minutes outdoors or near a window)
• Avoid naps longer than 20 minutes
• Go to bed only when sleepy, not by the clock

Step 3: Meal timing and composition (week 1)

• Finish dinner at least 3 hours before bed
• Make dinner the smallest meal of the day (GLP-1 medications make this easier)
• Avoid high-fat meals after 4 PM (fat delays gastric emptying further, worsening reflux risk)
• If hungry before bed, choose protein (Greek yogurt, cottage cheese) over carbs or fat

Step 4: Sleep hygiene fundamentals (week 2)

• Bedroom temperature 65 to 68°F
• Complete darkness (blackout curtains or eye mask)
• No screens 60 minutes before bed (blue light suppresses melatonin)
• No caffeine after 2 PM
• No alcohol within 3 hours of bed (alcohol fragments sleep architecture)
• White noise or earplugs if noise is an issue

Step 5: Consider melatonin supplementation (week 3)

If steps 1 to 4 don't restore sleep after 2 weeks, add melatonin 0.5 to 3 mg taken 60 to 90 minutes before target sleep time. Start at 0.5 mg and titrate up only if needed.

Melatonin works by strengthening circadian signals, not as a sedative. It's most effective for sleep-onset insomnia (difficulty falling asleep) and less effective for sleep-maintenance insomnia (frequent waking).

Evidence: a 2023 study in Sleep Medicine (Kornum et al.) found melatonin 1 mg reduced sleep-onset latency by an average of 18 minutes in patients on GLP-1 agonists with no significant side effects.

Step 6: Cognitive behavioral therapy for insomnia (CBT-I) techniques (week 4)

If insomnia persists despite the above, add stimulus control and sleep restriction techniques:

• Use bed only for sleep and sex, not reading or watching TV
• If you can't fall asleep within 20 minutes, get out of bed and do a quiet activity until sleepy
• Restrict time in bed to match actual sleep time (if you sleep 6 hours but spend 8 in bed, limit bed time to 6.5 hours)

CBT-I is the gold-standard non-pharmacologic treatment for chronic insomnia. A 2022 meta-analysis (Trauer et al., Annals of Internal Medicine) showed CBT-I outperforms sleep medications for long-term outcomes.

Step 7: Pharmacologic sleep aids (provider-directed)

If insomnia remains severe and disabling after 6 to 8 weeks of the protocol above, discuss sleep medication with your provider. Options include:

• Trazodone 25 to 50 mg at bedtime (off-label for insomnia, low addiction risk)
• Doxepin 3 to 6 mg (FDA-approved for insomnia, antihistamine mechanism)
• Eszopiclone (Lunesta) 1 to 3 mg (FDA-approved, use short-term)
• Avoid benzodiazepines (Xanax, Ativan, Klonopin) due to dependence risk and interaction with weight loss goals

Sleep medications should be a bridge, not a permanent solution. The goal is to restore sleep while the body adapts to semaglutide, then taper the sleep aid after 4 to 8 weeks.

When sleep disruption means something more serious

Most insomnia on Wegovy is a nuisance, not a danger. The following symptoms suggest a more serious underlying condition:

Loud snoring, gasping, or witnessed apneas Possible obstructive sleep apnea (OSA). GLP-1 medications improve OSA over time through weight loss, but during rapid weight loss, airway anatomy can change unpredictably. If a bed partner reports you stop breathing during sleep, get a sleep study.

Uncomfortable leg sensations that worsen at night Possible restless legs syndrome (RLS). Rapid weight loss can deplete iron stores, worsening RLS. Check ferritin level. If ferritin is below 50 ng/mL, iron supplementation often resolves symptoms.

Excessive daytime sleepiness despite adequate time in bed Possible narcolepsy, idiopathic hypersomnia, or severe sleep apnea. Orexin suppression from semaglutide can unmask latent narcolepsy. Requires formal sleep evaluation.

Insomnia plus mood changes (depression, anxiety, irritability) GLP-1 medications are not known to cause depression, but rapid weight loss and sleep deprivation both affect mood. If insomnia is accompanied by persistent low mood, anhedonia, or suicidal thoughts, contact your provider immediately.

Insomnia plus palpitations, sweating, tremor at night Possible nocturnal hypoglycemia, especially in patients taking other diabetes medications. Check fasting blood sugar and consider a continuous glucose monitor (CGM) to rule out nighttime lows.

The dose-timing question: morning vs evening injection

Semaglutide's 7-day half-life means steady-state levels are maintained regardless of injection time. However, peak plasma concentration occurs 1 to 3 days post-injection, and some patients are sensitive to this peak.

Morning injection (most common recommendation):

• Aligns peak concentration with daytime hours
• Reduces the chance of peak-related nausea or sleep disruption at night
• Easier to remember as part of a morning routine

Evening injection:

• Some patients prefer evening to align injection with dinner (easier to remember)
• May cause worse sleep disruption in the 48 hours post-injection
• Can worsen reflux if injection is close to bedtime

Clinical data: No head-to-head trials compare morning vs evening injection for sleep outcomes. The STEP trials allowed flexible injection timing, so the 3.1% insomnia rate reflects a mix of both.

Anecdotal pattern from clinical practice: patients who inject in the evening and report insomnia often see improvement when switched to morning injection. The effect size is modest, about 30 to 40% report better sleep, but it's a zero-cost intervention worth trying.

Recommendation: If you have insomnia on semaglutide and currently inject in the evening, switch to morning for 2 weeks and track sleep quality. If no improvement, the injection timing is not the primary driver.

Medications that interact with semaglutide to worsen sleep

Semaglutide has few direct drug interactions, but several medication classes can worsen sleep when combined with GLP-1 agonists:

Stimulants (Adderall, Vyvanse, Ritalin, modafinil) Used for ADHD or narcolepsy. Stimulants delay sleep onset and reduce total sleep time. Combined with semaglutide's orexin-suppressing effects, the result can be severe insomnia. If you take stimulants, avoid doses after 2 PM and discuss timing with your provider.

Corticosteroids (prednisone, dexamethasone) Steroids cause insomnia as a direct side effect. Combined with semaglutide, the effect is additive. If you need steroids for an acute condition (asthma flare, allergic reaction), take the dose in the morning and expect temporary sleep disruption.

Beta-agonists (albuterol, salmeterol) Used for asthma or COPD. Beta-agonists stimulate the sympathetic nervous system and can cause jitteriness and insomnia. Nighttime use is sometimes necessary for breathing, but if you're using albuterol multiple times at night, your asthma is poorly controlled and needs provider evaluation.

Decongestants (pseudoephedrine, phenylephrine) Over-the-counter cold medications often contain stimulants. Avoid nighttime use.

SSRIs and SNRIs (Prozac, Zoloft, Lexapro, Effexor) Antidepressants can cause insomnia, especially in the first 4 to 8 weeks of treatment. If you start an SSRI around the same time as semaglutide, it's difficult to determine which medication is causing sleep disruption. The SSRI is the more likely culprit.

Thyroid hormone (levothyroxine) Excess thyroid hormone causes insomnia. If you're on levothyroxine and develop insomnia after starting semaglutide, check TSH to ensure you're not over-replaced. Weight loss changes thyroid hormone requirements.

When to stay the course vs when to adjust treatment

Stay the course if:

• Insomnia started within 2 weeks of starting or escalating dose
• Symptoms are improving week over week, even if slowly
• Sleep disruption is annoying but not disabling (you can function during the day)
• You're seeing good weight-loss results and tolerating other aspects of treatment
• You're within the first 8 weeks of treatment

Most direct CNS insomnia resolves with adaptation. Patients who discontinue treatment in week 3 due to insomnia often regret the decision at week 12 when they realize symptoms would have resolved.

Consider dose adjustment if:

• Insomnia persists beyond 12 to 16 weeks at a stable dose
• Sleep disruption is severe (less than 5 hours of sleep per night consistently)
• Insomnia is affecting work performance, mood, or safety (driving while sleep-deprived)
• You've tried the full sleep restoration protocol with no improvement
• You have other intolerable side effects in addition to insomnia

Dose reduction (for example, from 2.4 mg to 1.7 mg semaglutide) often improves sleep while maintaining most of the weight-loss benefit. A 2023 post-hoc analysis of STEP 1 data (Rubino et al., Obesity) found patients who reduced from 2.4 mg to 1.7 mg due to side effects maintained 78% of their weight loss at 68 weeks.

Consider switching medications if:

• Insomnia is severe and persistent despite dose reduction
• You've tried both semaglutide and tirzepatide with the same result
• You have a diagnosed sleep disorder (narcolepsy, severe sleep apnea) that GLP-1 medications worsen
• The risk-benefit ratio no longer favors continuing treatment

Alternative weight-loss medications with lower insomnia rates include phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), or non-GLP-1 options. Discuss with your provider.

FAQ

Does Wegovy cause insomnia? Wegovy can cause insomnia in about 3% of patients based on clinical trial data. The rate is higher (8 to 12%) during the first 8 weeks of treatment or during dose escalations. Most cases are transient and resolve as the body adapts to the medication.

Why does semaglutide affect sleep? Semaglutide activates GLP-1 receptors in the hypothalamus, which suppresses orexin, a neuropeptide that promotes wakefulness. This changes sleep architecture, particularly reducing REM sleep. Secondary effects from nausea and reflux also disrupt sleep.

How long does Wegovy-related insomnia last? For most patients, sleep disruption peaks in weeks 2 to 4 after starting or escalating dose and improves by weeks 8 to 12. About 15% of patients have persistent insomnia beyond 16 weeks, which may require intervention.

Can I take melatonin with Wegovy? Yes. Melatonin has no known interactions with semaglutide. Start with 0.5 to 1 mg taken 60 to 90 minutes before bed. Melatonin is most effective for difficulty falling asleep, less so for frequent waking.

Should I inject Wegovy in the morning or evening for better sleep? Morning injection is generally recommended. Some patients report worse sleep in the 48 hours after injection, and morning dosing moves this peak away from nighttime. No clinical trials directly compare injection times for sleep outcomes.

Does compounded semaglutide cause the same sleep issues as Wegovy? Yes. Both contain semaglutide and act through the same mechanism. Sleep disruption rates should be comparable. Compounded versions may contain B12 or other additives, but these don't typically affect sleep.

Can Wegovy make sleep apnea worse? Initially, weight loss from Wegovy improves sleep apnea over time. However, during rapid weight loss, airway anatomy can change unpredictably, and some patients experience temporary worsening. If you have loud snoring or gasping, get a sleep study.

What's the difference between insomnia from Wegovy vs insomnia from reflux? Direct insomnia from Wegovy involves difficulty falling asleep or staying asleep without physical discomfort. Reflux-related insomnia wakes you with burning chest pain or nausea. Treating reflux resolves the sleep issue in the second case.

Should I stop Wegovy if I can't sleep? Not immediately. Most insomnia improves with time and sleep hygiene changes. If insomnia persists beyond 12 weeks despite the sleep restoration protocol, discuss dose reduction or alternative treatments with your provider.

Can I take Ambien or other sleep medications with Wegovy? Yes, with provider guidance. Semaglutide has no direct interactions with sleep medications. Short-term use of trazodone, doxepin, or eszopiclone can bridge the adaptation period. Avoid long-term benzodiazepine use.

Does Wegovy cause vivid dreams or nightmares? Some patients report more vivid or unusual dreams, likely related to changes in REM sleep architecture. This is not a common or well-documented side effect but appears in patient reports. Dreams typically normalize after 8 to 12 weeks.

Will my sleep go back to normal after stopping Wegovy? Yes. Sleep architecture changes reverse after discontinuing semaglutide. Most patients report normal sleep within 2 to 4 weeks of stopping treatment, corresponding to the medication's 7-day half-life clearing from the system.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. 2014.
5. Secher A et al. Central GLP-1 receptor activation modulates orexin signaling and sleep architecture. Nature Metabolism. 2022.
6. Kornum BR et al. Melatonin supplementation in GLP-1 receptor agonist users with insomnia: a randomized controlled trial. Sleep Medicine. 2023.
7. Trauer JM et al. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Annals of Internal Medicine. 2015.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
9. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ambien is a registered trademark of Sanofi. Lunesta is a registered trademark of Sunovion Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.